Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience
暂无分享,去创建一个
L. Macovei | R. Sascău | C. Adam | D. Marcu | C. Stătescu | C. Arsenescu-georgescu | D. Șalaru | M. Balasanian | D. Dorobantu | C. Arsenescu-Georgescu
[1] aguda y crónica,et al. Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2022, Revista espanola de cardiologia.
[2] S. Sideris,et al. Permanent pacemaker implantation in unexplained syncope patients with electrophysiology study-proven atrioventricular node disease. , 2022, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[3] C. Vlachopoulos,et al. Permanent pacemaker implantation in unexplained syncope patients with borderline sinus bradycardia and electrophysiology study‐proven sinus node disease , 2020, Journal of arrhythmia.
[4] Julie A. Johnson,et al. Pharmacogenetic factors affecting β-blocker metabolism and response , 2020, Expert opinion on drug metabolism & toxicology.
[5] Juan Jiménez-Jáimez,et al. Bloqueo auriculoventricular en pacientes en tratamiento con fármacos bradicardizantes. Variables predictoras de la necesidad de implante de marcapasos , 2020 .
[6] J. Marine,et al. Evaluating and managing bradycardia. , 2020, Trends in cardiovascular medicine.
[7] M. Jiménez-Navarro,et al. Atrioventricular block in patients undergoing treatment with bradycardic drugs. Predictors of pacemaker requirement. , 2020, Revista espanola de cardiologia.
[8] 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.
[9] Sergio Raposeiras-Roubín,et al. Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019 , 2019, Revista Española de Cardiología.
[10] C. Torp-Pedersen,et al. Rate- and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia. , 2019, Heart rhythm.
[11] M. Gold,et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.
[12] B. Ibáñez,et al. Role of beta-blockers in cardiovascular disease in 2019. , 2019, Revista espanola de cardiologia.
[13] M. Gold,et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. , 2019, Circulation.
[14] Anouk L. M. Eikendal,et al. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. , 2019, JACC. Heart failure.
[15] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[16] Deepak L. Bhatt,et al. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. , 2018, The American journal of medicine.
[17] David Moher,et al. Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: A systematic review of systematic reviews , 2018, PloS one.
[18] K. Patton,et al. Adverse drug reactions , 2018, Anaesthesia.
[19] R. Nordin,et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. , 2017, Journal of geriatric cardiology : JGC.
[20] K. Swedberg,et al. Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? , 2017, Journal of the American College of Cardiology.
[21] J. Lekakis,et al. Permanent pacemaker implantation in octogenarians with unexplained syncope and positive electrophysiologic testing. , 2017, Heart rhythm.
[22] J. Lindh,et al. Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting , 2016, PloS one.
[23] Thomas Bürkle,et al. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs , 2015, Pharmacoepidemiology and drug safety.
[24] S. Tobe,et al. Contemporary use of β-blockers: clinical relevance of subclassification. , 2014, The Canadian journal of cardiology.
[25] David G Strauss,et al. Evaluating strict and conventional left bundle branch block criteria using electrocardiographic simulations. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[26] M. Sweeney. Not So Temporary Pacing , 2013, Journal of cardiovascular electrophysiology.
[27] M. Pletcher,et al. Risk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice. , 2013, The American journal of medicine.
[28] Lluís Mont,et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.
[29] Lluís Mont,et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[30] James L. Netterville,et al. Clinical Practice Guideline , 2013, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[31] A. Khwaja. KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.
[32] T. Chang,et al. Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps. , 2011, Journal of the American College of Cardiology.
[33] W. Frishman,et al. β‐Adrenergic Blockers , 2011, Journal of clinical hypertension.
[34] R. Wachter,et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial , 2011, European journal of heart failure.
[35] M. Helfand,et al. Drug Class Review: Beta Adrenergic Blockers , 2009 .
[36] C. Schneider,et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.
[37] Warren M. Smith,et al. Metoprolol-induced hyperkalaemia in chronic respiratory acidosis. , 2007, The New Zealand medical journal.
[38] S. Nattel,et al. Adrenergic control of a constitutively active acetylcholine-regulated potassium current in canine atrial cardiomyocytes. , 2007, Cardiovascular research.
[39] J. Hawboldt,et al. Possible Metoprolol-Induced Hyperkalemia , 2006 .
[40] K. Swedberg,et al. Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.
[41] C. Coffey,et al. Adverse effects of -blocker therapy for patients with heart failure: A quantitative overview of ran , 2004 .
[42] David Zeltser,et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. , 2004, Journal of the American College of Cardiology.
[43] S. Efrati,et al. Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants , 2002, Pharmacoepidemiology and drug safety.
[44] M. Kapeliovich,et al. Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. , 2000, The Israel Medical Association journal : IMAJ.
[45] O. Ashouri. Metoprolol-induced hyperkalemia in a diabetic with advanced renal failure. , 1985, Archives of internal medicine.
[46] A. Levin,et al. Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.
[47] Michael H. Olsen,et al. ESH / ESC Guidelines for the management of arterial hypertension , 2013 .
[48] Grupo de Trabajo,et al. Documento de Consenso de Expertos sobre bloqueadores de los receptores β-adrenérgicos , 2005 .
[49] M. Helfand,et al. Drug Class Review on Beta Adrenergic Blockers , 2005 .
[50] K. Swedberg,et al. Expert consensus document on b-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology Task Force Members , Jos , 2004 .
[51] K. Swedberg,et al. Blockers in Chronic Heart Failure , 2003 .
[52] M. Rademaker. Do Women Have More Adverse Drug Reactions? , 2001, American journal of clinical dermatology.
[53] P. Timmermans,et al. Differential pharmacological properties of beta-adrenoceptor blocking drugs. , 1983, Journal of cardiovascular pharmacology.
[54] P. Timmermans,et al. Differential Pharmacological Properties of β‐Adrenoceptor Blocking Drugs , 1983 .
[55] Anouk L. M. Eikendal,et al. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women , 2022 .
[56] Y. Yokoyama,et al. Clinical Pharmacology: Advances and Applications Dovepress Severe Iatrogenic Bradycardia Related to the Combined Use of Beta-blocking Agents and Sodium Channel Blockers , 2022 .